Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (21-30 of 434) with videos related to

Pageof 44
Sort By:
The Lancet. Oncology|December 7, 2017
Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesisNaval Daver, Dimitrios P Kontoyiannis
Blood|April 1, 2021
Taking aim at IDH in fitter patients with AMLAndrew H Wei, Naval Daver
Blood Cancer Journal|May 28, 2021
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithmNaval Daver, Sangeetha Venugopal, Farhad Ravandi
Current Opinion in Hematology|January 11, 2017
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategiesRita Assi, Srdan Verstovsek, Naval Daver
Frontiers in Oncology|May 3, 2021
Editorial: The Biological Landscape of Immunotherapy in AMLAlessandro Isidori, Naval Daver, Antonio Curti
Future Oncology (London, England)|September 28, 2016
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognitionMaliha Khan, Maryam Sarfraz, Naval Daver
Current Hematologic Malignancy Reports|February 25, 2021
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid LeukemiaSangeetha Venugopal, Naval Daver, Farhad Ravandi
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid LeukemiaFadi Haddad, Amer M Zeidan, Naval Daver
Blood|September 24, 2024
How I treat patients with AML using azacitidine and venetoclaxAndrew H Wei, Sun Loo, Naval Daver
Pharmacological Reviews|September 25, 2016
Targeting Immune Checkpoints in Hematologic MalignanciesGheath Alatrash, Naval Daver, Elizabeth A Mittendorf
Pageof 44

Showing results (21-30 of 434) with videos related to

Sort By:
Pageof 44
The Lancet. Oncology|December 7, 2017
Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesisNaval Daver, Dimitrios P Kontoyiannis
Blood|April 1, 2021
Taking aim at IDH in fitter patients with AMLAndrew H Wei, Naval Daver
Blood Cancer Journal|May 28, 2021
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithmNaval Daver, Sangeetha Venugopal, Farhad Ravandi
Current Opinion in Hematology|January 11, 2017
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategiesRita Assi, Srdan Verstovsek, Naval Daver
Frontiers in Oncology|May 3, 2021
Editorial: The Biological Landscape of Immunotherapy in AMLAlessandro Isidori, Naval Daver, Antonio Curti
Future Oncology (London, England)|September 28, 2016
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognitionMaliha Khan, Maryam Sarfraz, Naval Daver
Current Hematologic Malignancy Reports|February 25, 2021
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid LeukemiaSangeetha Venugopal, Naval Daver, Farhad Ravandi
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid LeukemiaFadi Haddad, Amer M Zeidan, Naval Daver
Blood|September 24, 2024
How I treat patients with AML using azacitidine and venetoclaxAndrew H Wei, Sun Loo, Naval Daver
Pharmacological Reviews|September 25, 2016
Targeting Immune Checkpoints in Hematologic MalignanciesGheath Alatrash, Naval Daver, Elizabeth A Mittendorf
Pageof 44